Callisto CEO Dr. Gary Jacob Discusses Research Progress on New Anti-Cancer Drug Candidates in Interview with WallSt.net; Company Chief to Provide Corporate Overview of KAL's Drug Development Programs.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Callisto Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :KAL) (FWB (Fixed Wireless Broadband) See fixed wireless. :CA4), a developer of new drug therapies in the fight against hematologic hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancers and related diseases, has announced the online availability of an audio interview given by CEO/CSO Dr. Gary S. Jacob to online investor information service, WallSt.net, in which he discusses the Company's pipeline of drug development programs, including anti-cancer drugs designed to treat patients with leukemia and multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . "The interview gave me the opportunity to provide a good overview of Callisto's ongoing development programs," said Dr. Jacob. "We have a significant pipeline of drugs under development to address important medical needs for a significant number of people diagnosed with very serious cancers, such as leukemia and multiple myeloma, who have run out of treatment options under the currently available therapies. We also are making excellent progress in a number of other drug development programs that we believe will ensure Callisto will deliver a continued stream of innovative treatments." In the interview, Dr. Jacob provides background on the Company's leading drug candidates, which are being developed for relapsed cancer patients who have developed resistance to drug therapies currently available. Atiprimod, a drug designed to treat relapsed multiple myeloma patients, is currently in Phase I/IIa clinical trials. Annamycin, a drug with a novel therapeutic profile is being developed as a therapy for patients with relapsed leukemia. Dr. Jacob also discusses Callisto's preclinical programs to develop drugs for ulcerative colitis ulcerative colitis Inflammation of the colon, especially of its mucous membranes. The inflamed membranes develop patches of tiny ulcers, and the diarrhea contains blood and mucus. , as well as the Company's homeland security research program focused on the development of a drug to protect against staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. and streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. biowarfare agents. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has designated Annamycin and Atiprimod as "orphan drugs." Commercial advantages of that designation include marketing exclusivity protection when the drugs are approved for use. To listen to the interview, please visit: http://www.WallSt.net. About WallSt.net WallSt.net, owned by Digital Wall Street, is an online open network financial community that provides a number of services and tools to investors, including financial and market news, reports, and conferences. It can be found at http://www.WallSt.net. About Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical company focused on the development of drugs to treat cancer and osteolytic osteolytic adjective Causing bone breakdown bone disease. Callisto has two lead drugs in clinical development, Annamycin to treat relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate a clinical trial of Annamycin in relapsed acute lymphoblastic leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. patients in 4Q 2005. Annamycin, a drug from the anthracycline family, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase I/IIa clinical trial in relapsed multiple myeloma patients, and is a small-molecule, orally available drug with antiproliferative and antiangiogenic an·ti·an·gi·o·gen·ic adj. Inhibiting the growth of blood vessels. antiangiogenic activity. Callisto also has drugs in preclinical development for gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. Callisto is also listed on the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. under the ticker symbol CA4. For additional information, visit www.callistopharma.com. Forward-Looking Statements Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion